Dietmar Zehn
- Immunology top 0.2%
- Immune Cell Function and Interaction 61
- T-cell and B-cell Immunology 61
- Immunotherapy and Immune Responses 36
- Oncology top 0.5%
- CAR-T cell therapy research 19
- Cancer Immunotherapy and Biomarkers 12
- Virology top 5%
- Hepatology top 5%
- Cancer Research top 5%
-
- Diabetes and associated disorders 4
-
- Single-cell and spatial transcriptomics 3
- Protein Tyrosine Phosphatases 3
- Co-authors
- Michael J. BevanDaniel T. UtzschneiderDaniel E. SpeiserAxel KalliesSarah Y. LeeWerner HeldRobert ThimmeFrancesca Alfei
- Cited by
- ImmunologyOncologyVirology
- Partner nations
- GermanySwitzerlandUnited States
In The Last Decade
Dietmar Zehn
84 papers receiving 7.4k citations
Hit Papers
Peers
Comparison fields: 5 of 117
- Immunology 5.7k
- Oncology 3.5k
- Virology 164
- Hepatology 252
- Cancer Research 398
Countries citing papers authored by Dietmar Zehn
This map shows the geographic impact of Dietmar Zehn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dietmar Zehn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dietmar Zehn more than expected).
Fields of papers citing papers by Dietmar Zehn
This network shows the impact of papers produced by Dietmar Zehn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dietmar Zehn. The network helps show where Dietmar Zehn may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Dietmar Zehn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 7 | |
| 4 | Functional T cells are capable of supernumerary cell division and longevitybreakdown → | 2023 | 111 |
| 5 | 2021 | 23 | |
| 6 | 2021 | 11 | |
| 7 | 2020 | 57 | |
| 8 | 2020 | 55 | |
| 9 | 2020 | 1 | |
| 10 | 2019 | 33 | |
| 11 | 2019 | 18 | |
| 12 | 2018 | 16 | |
| 13 | 2018 | 118 | |
| 14 | 2017 | 75 | |
| 15 | 2014 | 92 | |
| 16 | 2013 | 141 | |
| 17 | 2013 | 10 | |
| 18 | 2010 | 139 | |
| 19 | 2010 | 27 | |
| 20 | 2007 | 13 |
About Dietmar Zehn
Dietmar Zehn is a scholar working on Immunology, Oncology and Hepatology, having authored 84 papers that have together received 7.5k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (61 papers), T-cell and B-cell Immunology (61 papers), Immunotherapy and Immune Responses (36 papers), CAR-T cell therapy research (19 papers), Cancer Immunotherapy and Biomarkers (12 papers), Diabetes and associated disorders (4 papers), Single-cell and spatial transcriptomics (3 papers) and Protein Tyrosine Phosphatases (3 papers). The work is most often cited by research in Immunology (5.7k citations), Oncology (3.5k citations) and Virology (164 citations). Dietmar Zehn has collaborated with scholars based in Germany, Switzerland and United States. Frequent co-authors include Michael J. Bevan, Daniel T. Utzschneider, Daniel E. Speiser, Axel Kallies, Sarah Y. Lee, Werner Held, Robert Thimme, Francesca Alfei, Ben Youngblood and Maike Hofmann. Their work appears in journals such as Nature Communications, Immunity, The Journal of Immunology, Cell Reports and Nature Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.